ProMetic Life Sciences Inc. (TSE:PLI) was up 2.3% during mid-day trading on Thursday . The stock traded as high as C$1.78 and last traded at C$1.78. Approximately 514,291 shares traded hands during trading, a decline of 55% from the average daily volume of 1,144,853 shares. The stock had previously closed at C$1.74.
Several equities research analysts have recently issued reports on PLI shares. National Bank Financial reduced their price objective on shares of ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating on the stock in a research report on Wednesday, November 15th. Cantor Fitzgerald reiterated an “overweight” rating on shares of ProMetic Life Sciences in a research report on Monday, November 20th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of C$3.50.
The firm has a market cap of $1,210.00, a PE ratio of -10.00 and a beta of 2.49.
ProMetic Life Sciences (TSE:PLI) last released its quarterly earnings data on Monday, November 13th. The company reported C($0.01) earnings per share (EPS) for the quarter. ProMetic Life Sciences had a negative net margin of 73.85% and a negative return on equity of 48.83%.
In other news, Director Steven J. Burton sold 98,075 shares of ProMetic Life Sciences stock in a transaction that occurred on Friday, January 19th. The shares were sold at an average price of C$1.54, for a total transaction of C$151,035.50.
ILLEGAL ACTIVITY NOTICE: This piece was first reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright legislation. The correct version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/03/prometic-life-sciences-pli-trading-up-2-3.html.
About ProMetic Life Sciences
Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.
Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.